Nonalcoholic steatohepatitis associated with metabolic syndrome: Relationship to insulin resistance and liver histology

Journal of Clinical Gastroenterology

Volumn 48, Issue 10, 2014, Pages 883-888

  Jung, Kyong Yeun ^a   Cho, Sun Young ^a   Kim, Hyung Joon ^a   Kim, Suk Bae ^a   Song, Il Han ^a  

^a Dankook University College of Medicine   (South Korea)

Author keywords

Homeostasis model assessment of insulin resistance (HOMA IR); Insulin resistance; Metabolic syndrome; Nonalcoholic steatohepatitis (NASH)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONALCOHOLIC FATTY LIVER; TRIACYLGLYCEROL BLOOD LEVEL; ANALYSIS; BIOPSY; BLOOD; COMPLICATION; ENZYMOLOGY; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; BLOOD GLUCOSE; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; LIVER CIRRHOSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84916234057     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/mcg.0000000000000065     Document Type: Article

References (34)

1. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 1999;116: 1413-1419.
2. Kopec KL, Burns D. Nonalcoholic fatty liver disease: A review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011;26: 565-576.
3. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol. 2010;5: 145-171.
4. Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol. 2012;47: 215-225.
5. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10: 330-344.
6. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. Cleve Clin J Med. 2008;75: 721-728.
7. Angelico F, Del Ben M, Conti R, et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2005;90: 1578-1582.
8. Sohn JH, Kim TY. Recent update on pathogenesis of nonalcoholic fatty liver disease. Korean J Med. 2010;79: 461-474.
9. Schreuder TC, Verwer BJ, van Nieuwkerk CM, et al. Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol. 2008;14: 2474-2486.
10. Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-2497.
11. Wilson PW, Grundy SM. The metabolic syndrome. Practical guide to origins and treatment: Part I. Circulation. 2003;108: 1422-1424.
12. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52: 913-924.
13. Angelico F, Del Ben M, Conti R, et al. Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol. 2003;18: 588-594.
14. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55: 2005-2023.
15. Weisell RC. Body mass index as an indicator of obesity. Asia Pac J Clin Nutr. 2002;11: S681-S684.
16. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28: 412-419.
17. Brunt EM. Nonalcoholic steatohepatitis: Definition and pathology. Semin Liver Dis. 2001;21: 3-16.
18. Perez Aquilar F, Benlloch S, Berenquer M, et al. Non-alcoholic steatohepatitis: Physiopathological, clinical and therapeutic implications. Rev Esp Enferm Dig. 2004;628-639.
19. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes. 2001;50: 1844-1850.
20. Rector RS, Thyfault JP, Wei Y, et al. Non-alcoholic fatty liver disease and the metabolic syndrome: An update. World J Gastroenterol. 2008;14: 185-192.
21. Yilmaz Y. NAFLD in the absence of metabolic syndrome: Different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin Liver Dis. 2012;32: 14-21.
22. Kwak MS, Kim D, Chung GE, et al. Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. Clin Mol Hepatol. 2012;18: 383-390.
23. Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology. 1998;114: 842-845.
24. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: A review and update. Dig Dis Sci. 2010;55: 560-578.
25. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology. 2006;43: S99-S112.
26. Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: Clinical implications and treatment. Nutr Clin Pract. 2013;28: 40-51.
27. Garcia-Monzon C, Martin-Perez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol. 2000;33: 716-724.
28. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30: 1356-1362.
29. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118: 1117-1123.
30. Fassio E, Alvarez E, Domínguez N, et al. Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies. Hepatology. 2004;40: 820-826.
31. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: Human data. Clin Liver Dis. 2007;11: 75-104.
32. Day CP. Natural history of NAFLD: Remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129: 375-378.
33. Adams LA, Lymp JF St, Sauver J, et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology. 2005;129: 113-121.
34. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7: 234-238.